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InflammationThe pro-inflammatory leukotrienes (LTs) are formed from arachidonic acid (AA) in activated leukocytes,
where 5-lipoxygenase (5-LO) translocates to the nuclear envelope to assemble a functional complex with
the integral nuclear membrane protein 5-LO-activating protein (FLAP). FLAP, a MAPEG family member,
facilitates AA transfer to 5-LO for efficient conversion, and LT biosynthesis critically depends on FLAP.
Here we show that the novel LT biosynthesis inhibitor BRP-187 prevents the 5-LO/FLAP interaction at
the nuclear envelope of human leukocytes without blocking 5-LO nuclear redistribution. BRP-187 inhib-
ited 5-LO product formation in human monocytes and polymorphonuclear leukocytes stimulated by
lipopolysaccharide plus N-formyl-methionyl-leucyl-phenylalanine (IC50 = 7–10 nM), and upon activation
by ionophore A23187 (IC50 = 10–60 nM). Excess of exogenous AA markedly impaired the potency of BRP-
187. Direct 5-LO inhibition in cell-free assays was evident only at >35-fold higher concentrations, which
was reversible and not improved under reducing conditions. BRP-187 prevented A23187-induced 5-LO/
FLAP complex assembly in leukocytes but failed to block 5-LO nuclear translocation, features that were
shared with the FLAP inhibitor MK886. Whereas AA release, cyclooxygenases and related LOs were unaf-
fected, BRP-187 also potently inhibited microsomal prostaglandin E2 synthase-1 (IC50 = 0.2 lM), another
MAPEG member. In vivo, BRP-187 (10 mg/kg) exhibited significant effectiveness in zymosan-induced
murine peritonitis, suppressing LT levels in peritoneal exudates as well as vascular permeability and neu-
trophil infiltration. Together, BRP-187 potently inhibits LT biosynthesis in vitro and in vivo, which seem-
ingly is caused by preventing the 5-LO/FLAP complex assembly and warrants further preclinical
evaluation.
 2016 Elsevier Inc. All rights reserved.fMLP, N-
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Leukotrienes (LT) are pro-inflammatory lipid mediators derived
from arachidonic acid (AA) and formed via the 5-lipoxygenase (5-
LO) pathway [1]. Upon activation of leukocytes, AA is released by
cytosolic phospholipase (cPLA2) and converted to 5(S)-hydroper
oxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HPETE) in a first-
step catalysis of 5-LO. In a second 5-LO-mediated reaction, 5-
HPETE is then converted to the unstable epoxide LTA4, a common
precursor that can be transformed by LTC4 synthases to the bron-
choconstrictive cysteinyl-leukotrienes (cysLTs) or by LTA4 hydro-
lase to the chemoattractant LTB4 [2]. Due to the pro-
inflammatory action of LTs, inhibitors against the enzymes in the
LT biosynthetic pathway (i.e., 5-LO, LTA4 hydrolase, LTC4 syn-
thases) [3–5] or compounds that act as antagonists at LT receptors
[6] have been developed. However, besides CysLT1 receptor antag-
onists such as montelukast or pranlukast that are clinically used to
treat (childhood) asthma, inhibitors against biosynthetic enzymes
within the 5-LO pathway are not widely used in the clinics, cer-
tainly due also to significant side effects like liver toxicity [7]. As
a consequence, an unmet need to develop new anti-LT compounds
remains.
A promising target that is involved in the biosynthesis of the
precursor LTA4 is the 5-LO-activating protein (FLAP), which
in vivo is seemingly indispensable for LT formation [8,9]. FLAP, a
member of the MAPEG family (membrane-associated proteins in
eicosanoid and glutathione metabolism), is an integral nuclear
membrane protein lacking enzymatic activity but it is playing aA B
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Fig. 1. BRP-187 potently inhibits 5-LO product formation in human PMNL and monocytes
1,2-oxazol-5-yl)-5-[(2-methyl phenyl)methoxy)phenol), and the novel derivative BRP-
acid). (B) Inhibition of 5-LO activity by BRP-187 in cell-based and cell-free assays. Hum
15 min at 37 C prior stimulation by 2.5 lM A23187. After 10 min, 5-LO product formatio
5  106 cells/ml) were incubated with BRP-187 or vehicle (DMSO, 0.1%) at 4 C for 15 mi
added. After 10 min 5-LO product formation was determined. (C–G) Human PMNL (C, F) o
15 min at 37 C. Cells were then stimulated for 10 min with 2.5 lM A23187 with or with
stimulated with 1 lM fMLP for 10 min (F, G). (E) Inhibition of single 5-LO products forme
by BRP-187, see (D). For the corresponding 100% control, typical ranges of 5-LO products f
LTC4: 0.5–0.7 ng/106 cells. In all assays, 5-LO products LTB4, its trans-isomers, and 5-HETE
percentage of control (100%), mean ± SEM, n = 4.crucial role in LT formation in various intact leukocytes [8,10].
Upon activation, 5-LO redistributes from soluble cellular pools to
the perinuclear region and interacts with FLAP at the nuclear mem-
brane [11,12]. FLAP facilitates AA substrate transfer to 5-LO [13,14]
and AA is required for assembling the 5-LO/FLAP complex. In fact,
FLAP inhibitors efficiently inhibit 5-LO product formation in intact
cells which can be overcome, at least in part, by supplementation
of high concentrations of exogenous AA [9,11,14–16]. Notably,
FLAP inhibitors fail to inhibit 5-LO activity in cell-free assays
[17,18], implying that FLAP is operative in 5-LO product biosynthe-
sis only in the cellular context. The crystal structure of FLAP pro-
vided substantial insights into the binding site of AA and also
clarified how FLAP inhibitors (i.e., MK591) might compete with
AA from binding to FLAP [19]. Moreover, we recently showed that
FLAP may help to coordinate 5-LO membrane binding with
unblocking active AA-binding site access that is corked by Y181
and F177 [14]. Together, a dynamic 5-LO/FLAP complex is crucial
for LTA4 biosynthesis and represents, besides direct targeting of
5-LO enzymatic activity, a valuable target for pharmacological
inhibitors in order to effectively and selectively intervene with
LT-related disorders.
Within the frame of a recent screening approach for novel
chemotypes that antagonize FLAP using a combined ligand- and
structure based pharmacophore model [20], compound 1 (2-[4-(4
-chlorophenyl)-3-methyl-1,2-oxazol-5-yl)-5-[(2-methylphenyl)m
ethoxy)phenol, Fig. 1A was identified as moderate inhibitor of 5-LO
product biosynthesis in human neutrophils (IC50 = 4.4 lM), with
unclear mode of action. In a follow-up study aiming to improveC
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. (A) Chemical structures of parental compound 1 (2-[4-(4-chlorophenyl)-3-methyl-
187 (4-(4-chlorophenyl)-5-[4-(quinolin-2-ylmethoxy)phenyl]isoxazol-3-carboxylic
an PMNL (5  106) were pre-incubated with BRP-187 or 0.1% DMSO as vehicle for
n was assessed. Purified 5-LO (0.5 lg/ml) or PMNL homogenates (corresponding to
n, samples were pre-warmed for 30 s at 37 C, and 2 mM CaCl2 and 20 lM AA were
r monocytes (D, E, G) were pre-incubated with BRP-187 or 0.1% DMSO as vehicle for
out 50 lM AA (C, D), or first primed with 1 lg/ml LPS for 20 min at 37 C and then
d in A23187-activated monocytes including trans-isomers of LTB4, 5-HETE and LTC4
ormed are: LTB4 and its isomers: 20–30 ng/106 cells; 5-H(P)ETE: 10–15 ng/106 cells;
were analyzed by HPLC, whereas LTC4 was assessed by ELISA. Data are expressed as
U. Garscha et al. / Biochemical Pharmacology 119 (2016) 17–26 19the LT biosynthesis inhibitory potency of compound 1 through
interference with FLAP, the derivative BRP-187 (4-(4-chlorophe
nyl)-5-[4-(quinolin-2-ylmethoxy)phenyl]isoxazol-3-carboxylic
acid, Fig. 1A was obtained that potently inhibited cellular 5-LO pro-
duct formation with an IC50 = 0.24 lM and >30-fold lower activity
against 5-LO directly in cell-free assays [21]. Here we (i) provide a
comprehensive analysis of BRP-187 on 5-LO product biosynthesis
in vitro and in vivo, (ii) reveal that this compound impedes the 5-
LO/FLAP complex assembly, and (iii) demonstrate potent anti-
inflammatory effectiveness of BRP-187 in a LT-related animal
model of inflammation.2. Materials and methods
2.1. Materials
BRP-187 was synthesized and characterized as previously
described by us [21]. Zileuton (N-(1-benzo[b]thien-2-ylethyl)-N-
hydroxyurea), Sequoia Research Products (Oxford, UK); MK886,
LTC4-d5 methyl ester and LTA4-methyl ester, Cayman Chemicals
(Ann Arbor, MI); PGH2, Larodan (Malmö, Sweden); IL-1b, Repro-
Tech (Hamburg, Germany); pyrrolidine-1, Calbiochem (Darmstadt,
Germany); EDTA and Nonidet P-40, AppliChem (Darmstadt, Ger-
many); RPMI media, glutamine, penicillin and streptomycin, PAA
(Coelbe, Germany); tritium-labeled [5,6,8,9,11,12,14,15-3H]AA,
Biotrend Chemicals GmbH (Cologne, Germany), Adenosine deami-
nase (Ada), AA, ATP-agarose, Ca2+-ionophore A23187, dextran,
dithiothreitol, fetal calf serum, formyl-methionyl-leucyl-phenylala
nine (fMLP), indomethacin, lipopolysaccharide (LPS), Triton X-100
and all other chemicals were purchased from Sigma-Aldrich (Tauf-
kirchen, Germany), unless stated otherwise. HPLC solvents were
from VWR (Darmstadt, Germany).2.2. Cells and cell isolation
Peripheral blood (University Hospital Jena, Germany) was with-
drawn from fasted (12 h) healthy adult volunteers that had not
taken any anti-inflammatory drugs during the last 10 days (with
consent), by venipuncture in heparinized tubes (16 IE heparin/ml
blood). The blood was then centrifuged (4000g, 20 min, 20 C) for
preparation of leukocyte concentrates. Leukocyte concentrates
were subjected to dextran sedimentation and centrifugation on
lymphocyte separation medium (LSM 1077, PAA, Colbe, Germany).
For isolation of polymorphonuclear leukocytes (PMNL), contami-
nating erythrocytes of pelleted PMNL were removed by hypotonic
lysis. PMNL were then washed twice in ice-cold PBS and finally
resuspended in PBS pH 7.4 containing 1 mg/ml glucose or in PBS
pH 7.4 containing 1 mg/ml glucose plus 1 mM CaCl2 (PGC buffer)
(purity >96–97%). Monocytes were isolated from the peripheral
blood mononuclear cell fraction, which was obtained after cen-
trifugation of leukocyte concentrates on LSM 1077, by adherence
(1.5 h at 37 C) to culture flasks (Greiner, Nuertingen, Germany)
at a cell density of 2  107 cells/ml RPMI 1640 medium containing
2 mM L-glutamine and 100 U/ml penicillin and 100 lg/ml strepto-
mycin). The purity of monocytes was >85%, defined by forward-
and side-light scatter properties and detection of the CD14 surface
molecule by flow cytometry (BD FACS Calibur, Heidelberg, Ger-
many). Monocytes were finally resuspended in ice-cold PGC buffer
for further experiments. For analysis of acute cytotoxicity of BRP-
187 during pre-incubation (i.e. 30 min), the viability of PMNL and
monocytes was analyzed by trypan blue exclusion using a Vi-cell
counter (Beckmann Coulter, Krefeld, Germany).
HEK293 and A549 cells used as source for expression of LTC4
synthase and mPGES-1 were obtained at LGC Standards (Wesel,Germany). Authentication of cell lines was carried out by STR anal-
yses (LGC Standards).
2.3. Expression, purification and activity assay of human recombinant
5-LO
Escherichia coli (BL21) was transformed with pT3-5-LO plasmid,
and recombinant 5-LO protein was expressed at 30 C as described
[22]. Cells were lysed in 50 mM triethanolamine/HCl pH 8.0, 5 mM
EDTA, 1 mM phenylmethanesulphonyl fluoride, soybean trypsin
inhibitor (60 lg/ml), and lysozyme (1 mg/ml), homogenized by
sonication (3  15 s), and centrifuged at 40,000g for 20 min at
4 C. The 40,000g supernatant (S40) was applied to an ATP-
agarose column to partially purify 5-LO as described [22]. Aliquots
of semi-purified 5-LO were diluted with ice-cold PBS containing
1 mM EDTA, and 1 mM ATP was added. Samples were pre-
incubated with the test compounds or vehicle (0.1% DMSO). After
10 min at 4 C, samples were pre-warmed for 30 s at 37 C, and
2 mM CaCl2 plus the indicated concentrations of AA were added
to start 5-LO product formation. The reaction was stopped after
10 min by addition of one volume of ice-cold methanol, and the
formed metabolites were analyzed by RP-HPLC as described [23].
5-LO products include the all-trans isomers of LTB4 as well as 5
(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-
HPETE) and its corresponding alcohol 5(S)-hydroxy-6-trans-8,11,
14-cis-eicosatetraenoic acid (5-HETE).
2.4. Determination of 5-lipoxygenase products in intact cells and in
corresponding homogenates
For determination of 5-LO products in intact PMNL (5  106) or
monocytes (2  106) cells were resuspended in 1 ml PGC buffer,
preincubated for 15 min at 37 C with test compounds or vehicle
(0.1% DMSO), and incubated for 10 min at 37 C with the indicated
stimuli. Ca2+-ionophore A23187 (2.5 lM) was added with or with-
out the indicated concentrations of AA for 10 min and the reaction
was stopped on ice by addition of 1 ml of methanol. Alternatively,
cells were first primed at 37 C with LPS (1 lg/ml) plus Ada (0.3 U/
ml) for 30 min. Formation of 5-LO products was started by addition
of 1 lM fMLP and after 5 min the reaction was stopped by metha-
nol. 30 ll 1 N HCl and 500 ll PBS, and 200 ng prostaglandin B1
were added and the samples were subjected to solid phase extrac-
tion on C18-columns (100 mg, UCT, Bristol, PA, USA). 5-LO prod-
ucts (LTB4 and its trans-isomers, 5-H(P)ETE), were analyzed by
HPLC and quantities calculated on the basis of the internal stan-
dard PGB1. CysLTs C4, D4 and E4 were not detected (amounts were
below detection limit), and oxidation products of LTB4 were not
determined.
For determination of 5-LO products in corresponding homoge-
nates, cell suspensions were resuspended in PBS containing
1 mM EDTA for 5 min at 4 C and sonicated (4  10 s, 4 C). Homo-
genates corresponding to 5  106 cells/ml were incubated with the
test compounds or vehicle (0.1% DMSO) for 15 min at 4 C, pre-
warmed for 30 s at 37 C and the reaction was started by the addi-
tion of 2 mM CaCl2 and 20 lM AA. The reaction was stopped after
10 min and the samples were analyzed as described for intact cells
above.
2.5. Determination of cysLT formation in monocytes
Monocytes (5  106 cells) were resuspended in 1 ml PGC buffer,
incubated with the test compounds or vehicle (0.1% DMSO) for
15 min at 37 C, primed with 1 lg/ml LPS for 20 min and stimu-
lated with 1 lM fMLP for 10 min at 37 C. The reaction was
stopped on ice, and supernatants were collected after centrifuga-
tion at 600g for 10 min at 4 C. CysLTs were assessed by ELISA,
20 U. Garscha et al. / Biochemical Pharmacology 119 (2016) 17–26which detects LTC4, LTD4 and LTE4 according to the manufacturer’s
(Enzo Life Sciences International Inc., Lörrach, Germany)
instructions.
2.6. Analysis of 5-LO redistribution by immunofluorescence
microscopy (IF)
For analysis of 5-LO and FLAP distribution in monocytes, PBMC
were seeded in RPMI medium containing 2 mM L-glutamine and
100 U/ml penicillin and 100 lg/ml streptomycin onto glass cover-
slips in a 12-well plate and cultured for 1.5 h. Cells were washed
with PGC buffer and pre-incubated with test compounds or vehicle
10 min at 37 C in PGC buffer prior to activation. For analysis of
PMNL, cells were pre-incubated with test compounds or vehicle
for 10 min at 37 C resuspended in PGC buffer and centrifuged onto
poly-D-lysine coated glass coverslips (10g for 2 s) prior to stimula-
tion. Monocytes and PMNL were then activated for 3 min and
stopped by fixation with 4% paraformaldehyde solution. Acetone
(3 min, 4 C) and 0.25% Triton X-100 (10 min) were used for per-
meabilization prior to blocking with non-immune goat serum.
Samples were incubated with mouse monoclonal anti-5-LO anti-
body (1:100; generous gift by Dr. Dieter Steinhilber (Goethe
University Frankfurt, Germany) and rabbit polyclonal anti-FLAP
antibody (5 lg/ml; Abcam (Cambridge, UK) at 4 C [9]. 5-LO and
FLAP were stained with the fluorophore-labeled secondary anti-
bodies; Alexa Fluor 488 goat anti-rabbit (1:1000) and Alexa Fluor
555 goat anti-mouse (1:1000), obtained at Invitrogen (Darmstadt,
Germany) [9]. Nuclear DNA was stained with DAPI (Invitrogen).
Samples were analyzed by a Zeiss Axiovert 200 M microscope,
and a Plan Neofluar 100/1.30 Oil (DIC III) objective (Carl Zeiss,
Jena, Germany). An AxioCam MR camera (Carl Zeiss, Jena, Ger-
many) was used for image acquisition
2.7. Determination of PGE2 synthase activity in a cell-free assay
Preparations of A549 cells and determination of mPGES-1 activ-
ity was performed as described previously [24]. In brief, A549 cells
were treated with 2 ng/ml Il-1b for 72 h at 37 C, 5% CO2. Cells were
harvested, sonicated and homogenized. The homogenate was sub-
jected to differential centrifugation at 10,000g for 10 min and
174,000g for 1 h at 4 C. The pellet (microsomal fraction) was
resuspended in 1 ml homogenization buffer. Microsomal mem-
branes were diluted in potassium phosphate buffer (0.1 M, pH
7.4) containing 2.5 mM glutathione. Test compounds or vehicle
were added, and after 15 min at 4 C reaction (100 ll total volume)
was initiated by addition of 20 lM PGH2. After 1 min at 4 C, the
reaction was terminated using stop solution (100 ll; 40 mM FeCl2,
80 mM citric acid, and 10 lM 11b-PGE2 as internal standard). PGE2
was separated by solid-phase extraction and analyzed by RP-HPLC
as described previously [24].
2.8. Determination of LTC4 synthase activity
HEK293 cells stably expressing LTC4 synthase (HEK_LTC4-S)
were used to generate microsomes containing LTC4 synthase.
Briefly, HEK_LTC4-S were frozen in liquid nitrogen and sonicated
3  20 s at 4 C in homogenization buffer (0.1 potassium phos-
phate buffer, pH 7.4, 1 mM phenylmethylsulfonylfluoride, 60 lg/
ml soybean trypsin inhibitor, 1 lg/ml leupeptin, 2.5 mM glu-
tathione, and 250 mM sucrose). Lysates were sequentially cen-
trifuged at 10,000g, 10 min at 4 C and 174,000  g for 1 h at
4 C. The microsomal fraction (2.5 lg) was resuspended in assay
buffer (0.1 M potassium buffer pH 7.4; plus 5 mM glutathione)
and preincubated with the test compound or vehicle (0.1% DMSO)
for 10 min at 4 C. The reactions were started by adding 1 lM LTA4-
methyl ester (Cayman, Ann Arbor, MI) and stopped after 10 minincubation at 4 C by 1 vol. ice-cold methanol. Acidified PBS and
LTC₄-methyl ester-d₅ as internal standard were added prior solid
phase extraction and LTC4 methyl ester formation was analyzed
by UPLC–MS/MS as described [25]. UPLC–MS/MS was carried out
on an Acquity UPLC BEH C18 column (1.7 lm, 2.1  50 mm,
waters) and a QTRAP 5500 Mass spectrometer (AB Sciex). LTC4
methyl ester and LTC4-d5 methyl ester (standard) were detected
by multiple reaction monitoring in the negative ion mode by a
method described previously [26].
2.9. Analysis of protein interaction by in situ proximity ligation assay
To analyze the in situ interaction of 5-LO with FLAP in mono-
cytes and PMNL, an in situ proximity ligation assay (PLA) was per-
formed, according to the manufacturers’ protocol [27] and as
described [11]. Samples were treated, fixed and incubated with
primary antibody as described for IF microscopy above. Cells were
then incubated with species specific secondary antibodies conju-
gated with oligonucleotides (PLA probe anti-mouse MINUS and
anti-rabbit PLUS) for 1 h at 37 C. By addition of two other circle-
forming DNA oligonucleotides and a ligase (30 min at 37 C) the
antibody-bound oligonucleotides form a DNA circle when the tar-
get proteins are less than 40 nm distant from each other. The
newly generated DNA circle was amplified by rolling circle ampli-
fication and visualized by hybridization with fluorescently labeled
oligonucleotides. Nuclear DNA was stained with DAPI. The PLA
interaction signal appears as a fluorescent spot and was analyzed
by fluorescence microscopy using a Zeiss Axiovert 200 M micro-
scope, and a Plan Neofluar 100/1.30 Oil (DIC III) objective as well
as a Plan Neofluar 40/1.30 Oil (DIC III) objective (Carl Zeiss, Jena,
Germany).
2.10. Determination of release of [3H]-labeled arachidonic acid
Release of [3H]-labeled AA from human monocytes was ana-
lyzed as described [28]. Briefly, cells were resuspended in medium
and incubated with 5 nM [3H]AA (corresponding to 0.5 lCi/ml,
specific activity 200 Ci/mmol) for 2 h at 37 C. Cells were collected,
washed to remove unincorporated [3H]AA, and resuspended in PBS
containing 1 mM CaCl2. The cells were pre-incubated with test
compounds or vehicle (0.1% DMSO) at 37 C for 15 min, and subse-
quently stimulated with 2.5 lM A23187 for 10 min at 37 C. The
reaction was stopped on ice (10 min) and cells were centrifuged.
Aliquots of the supernatants were combined with 2 ml Rotiszint
eco plus and assayed for radioactivity by scintillation counting
(Micro Beta Trilux, Perkin Elmer, Waltham, MA).
2.11. Murine peritonitis model
Male CD-1 mice (33–39 g, Charles River Laboratories, Calco,
Italy) were housed in a controlled environment (21 ± 2 C) and pro-
vided with standard rodent chow and water ad libitum. Mice were
allowed to acclimate for five days prior to experiments and were
kept at 12 h light–12 h dark schedule. Experiments were con-
ducted during the light phase. Animal care was in compliance with
Italian regulations on protection of animals used for experimental
and other scientific purpose (Ministerial Decree 116/92) and with
the European Economic Community regulations (Official Journal
of E.C. L 358/1 12/18/1986). Animal studies were approved by
the local ethics committee of the Univ. of Naples Federico II on
27 February 2014 (approval number 2014/18760).
Mice (n = 6 per experimental group; age of 8–9 weeks) received
BRP-187 (1, 3 or 10 mg/kg), MK886 (1 or 3 mg/kg), zileuton
(10 mg/kg) or vehicle (0.5 ml of 0.9% saline solution containing
2% DMSO), intraperitoneally (i.p.) 30 min prior to zymosan injec-
tion, according to a well-recognized experimental design for
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After boiling in PBS and centrifugation, zymosan (Sigma, Milan,
Italy) was prepared as a final suspension (2 mg/ml) in 0.9% (w/v)
saline and injected i.p. (0.5 ml) after sonication. Mice were killed
by inhalation of CO2 at the indicated time points followed by a
peritoneal lavage with 3 ml of cold PBS. After 60 s gentle manual
massage, 2 ml of exudates were collected, and infiltrated cells were
counted with a light microscope in a Burker’s chamber after vital
trypan blue staining. The samples were centrifuged (18,000g,
5 min, 4 C) and frozen (-80 C) for the myeloperoxidase (MPO)
assay (pellet) and for cysLT analysis (supernatant). The amounts
of cysLTs were assayed in the supernatant by EIA (Enzo Life
Sciences International Inc., Lörrach, Germany) according to manu-
facturer’s protocol; data are expressed as ng/ml.
MPO assay was carried out according to Rao et al. [30] with
minor modifications. Briefly, pellets from exudates were resus-
pended into 1.7 ml PBS (50 mM; pH6) containing 0.5%
hexadecyltrimethyl-ammonium bromide. To disrupt the cells, the
samples were sonicated, followed by a freeze-thawing for 3 times
and a second sonication step. After centrifugation (18,000g;
30 min) 20 ll of the supernatant was added to a 96-well plate.
The reaction was initiated by addition of 200 ll PBS (50 mM;
pH6) containing 0.167 mg/ml of o-dianisidine and 0.0005% hydro-
gen peroxide. The rate of change of absorbance was monitored in
kinetic mode using a plate reader (Biorad Imark microplate). Levels
of MPO were determined from the calibration curve using human
neutrophil MPO as reference standard. MPO levels were expressed
as units MPO per mouse.
Vascular permeability was assessed according to Kolaczkowska
et al. [31] with minor modifications. In brief, Evans blue dye was
solubilized in saline (5 mg/ml), diluted to give a constant dose of
40 mg/kg per mice (6 mice per group, with age of 8–9 weeks)
and injected intravenously (i.v.) into the caudal vein (0.3 ml),
immediately followed by peritonitis induction. After 30 min the
mice were euthanized by CO2 and exudates were collected after
peritoneal lavage with 3 ml of cold PBS. After centrifugation at
3000g for 5 min, the absorbance of the supernatants was measured
at 650 nm (Beckman Coulter DU730).2.12. Statistics
Data are expressed as mean ± S.E.M. IC50 values were calculated
from averaged measurements at 3–5 different concentrations of
the compounds by nonlinear regression using GraphPad Prism
software (San Diego, CA) one site binding competition. Data
obtained in animal experiments are given as mean ± SEM obtained
from 6 mice in total. Statistical evaluation of the data was per-
formed by one-way ANOVA followed by a Bonferroni or Tukey-
Kramer post hoc test for multiple comparisons respectively. A p
value <0.05 (⁄) was considered significant.Table 1
Overview of the IC50 values of BRP-187 for 5-LO product formation in various test
systems and assays.
Test system Assay condition IC50 [lM]
Isolated 5-LO 10 lM AA 2.1 ± 1.7
Homogenates (PMNL) 20 lM AA 2.2 ± 0.07
Intact PMNL A23187 0.06 ± 0.01
A23187 + 50 lM AA 0.4 ± 0.2
LPS/fMLP 0.01 ± 0.001
Intact monocytes A23187 0.01 ± 0.004
A23187 + 50 lM AA >1
LPS/fMLP 0.007 ± 0.0013. Results
3.1. BRP-187 potently inhibits cellular 5-LO product synthesis
In agreement with the results from our recent SAR study on 4,5-
diarylisoxazole-3-carboxylic acids [21], BRP-187 potently
repressed 5-LO product biosynthesis in intact A23187-activated
PMNL in a concentration-dependent manner, with IC50 = 60 nM
(Fig. 1B). However, BRP-187 was 35- and 37-fold less efficient in
inhibiting isolated 5-LO enzyme (IC50 = 2.1 lM) or 5-LO in crude
in homogenates (IC50 = 2.2 lM), respectively, assayed in cell-free
test systems (Fig. 1B). The higher potency of BRP-187 in intact cells
versus cell-free assays implied that besides 5-LO, the compound
may interfere with additional cellular determinants of 5-LO pro-duct biosynthesis such as cPLA2 or FLAP. Therefore, we investigated
suppression of 5-LO product biosynthesis in intact cells in more
detail by variation of the cell-based assay conditions. First, we sup-
plemented PMNL with exogenous AA in excess (50 lM) to circum-
vent cPLA2-mediated AA substrate supply and the absolute
requirement of FLAP [16,32,33]. As shown in Fig. 1C, also in the
presence of 50 lM AA, BRP-187 still suppressed 5-LO activity in
PMNL, but the IC50 shifted to 10-fold higher values (i.e., 0.4 lM).
Besides PMNL, we studied 5-LO activity also in human mono-
cytes. BRP-187 strongly suppressed 5-LO product biosynthesis in
A23187-activated monocytes (IC50 = 10 ± 4 nM) with significant
higher potency than in PMNL, and again supplementation of
50 lM AA caused >100-fold loss of potency (IC50 > 1 lM) (Fig. 1D).
Note that BRP-187 suppressed the synthesis of all 5-LO products
(i.e., LTB4, its trans-isomers, and 5-H(P)ETE) almost equally well
(Fig. 1E). As monocytes produce also cysLTs as 5-LO products, we
analyzed the effect of BRP-187 for repression of cysLT formation
in A23187-treated cells (monitored by ELISA), and a similar
concentration-dependent inhibition as for other 5-LO products
with IC50 = 9 ± 2 nM was observed (Fig. 1E). Of interest, upon stim-
ulation with the physiological relevant receptor-mediated agonists
LPS and fMLP [34], BRP-187 was most potent and blocked LTB4 for-
mation in PMNL or monocytes with IC50 values of 7 ± 1 and
10 ± 1 nM, respectively (Fig. 1F and G). The IC50 values of BRP-
187 are summarized in Table 1.3.2. BRP-187 barely alters 5-LO subcellular redistribution but disrupts
the interaction of 5-LO with FLAP
FLAP as an integral nuclear membrane protein may associate
with 5-LO after redistribution from the cytosol to the perinuclear
region upon cell activation [11,12]. FLAP inhibitors are able to
interrupt this interaction, which can be visualized in situ by PLA
[11]. 5-LO redistribution and colocalization with FLAP at the
nuclear membrane can be studied by IF microscopy [9,11], but
inconsistent observations were made concerning the effects of
FLAP inhibitors that somehow alter 5-LO subcellular localization
but do not unequivocally prevent translocation of 5-LO to the
nucleus [9,11,15,29].
We first analyzed the effects of BRP-187 on 5-LO subcellular
localization in human monocytes and PMNL, where colocalisation
of 5-LO and FLAP at the nuclear membrane in A23187-activated
cells can be clearly visualized by immunofluorescence (IF) micro-
scopy (Fig. 2A). The 5-LO inhibitor zileuton [35] and the FLAP inhi-
bitor MK886 [36] were used as negative and positive controls,
respectively [11]. In activated monocytes and PMNL both MK886
and BRP-187 failed to prevent movement of 5-LO to the perinu-
clear region (Fig. 2A). Zileuton, used as negative control, did not
affect 5-LO subcellular redistribution as expected and shown in
our recent study before [11]. However, using PLA in human mono-
cytes and PMNL, BRP-187 (0.1 lM) prevented the interaction
between 5-LO and FLAP at the nuclear membrane in activated cells,
and a comparable effect was obvious for cells treated with MK886
A100 µm
B
100 µm
Fig. 2. Effects of BRP-187 on 5-LO subcellular redistribution and 5-LO/FLAP interaction. (A) Subcellular localization of 5-LO and FLAP. Monocytes (left panel) or PMNL (right
panel) were pre-incubated with BRP-187 (1 lM), MK886 (300 nM) or vehicle (0.1% DMSO) for 10 min at 37 C, and then stimulated with 2.5 lM A23187 for 10 min at 37 C.
Images show single staining for 5-LO (red, top lane) and overlay of 5-LO (red) and FLAP (green) (bottom lane). Results are representative for 100 individual cells of three
independent experiments. (B) 5-LO/FLAP interaction. In situ PLA, using proximity probes against 5-LO and FLAP was performed in monocytes (left panel) and PMNL (right
panel) pre-incubated with BRP-187 (100 nM) or MK886 (100 nM) for 15 min at 37 C and stimulated with A23187 (2.5 lM) for 20 min. DAPI (blue) was used to stain the
nucleus and PLA signals (magenta dots) visualize 5-LO/FLAP interaction. Results are representative for 100 individual cells analyzed in three independent experiments. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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reported before [11]. Together, BRP-187 seemingly acts as FLAP
inhibitor and the potent suppression of 5-LO product biosynthesis
in intact cells from endogenous AA might be due to prevention of
5-LO/FLAP complex formation.
3.3. Effects of BRP-187 on 5-LO activity in cell-free assays
We next analyzed the effects of BRP-187 on 5-LO activity in
cell-free assays in more detail. Wash-out experiments using iso-
lated 5-LO revealed a complete reversibility of 5-LO inhibition by
BRP-187 (Fig. 3A). Also, when 5-LO inhibition by BRP-187 was
investigated in the presence of 0.01 or 0.1% Triton X-100, a non-
ionic detergent that should solubilize aggregates that may be
formed due to the lipophilic nature of BRP-187, the potency was
not or only hardly reduced (Fig. 3B). Thus, we conclude that inhibi-
tion of 5-LO by BRP-187 is caused by specific, reversible binding to
the 5-LO enzyme, albeit with apparent low affinity requiring high
IC50 values as compared to the potent repression of 5-LO product
synthesis in intact cells.
As for BRP-187, for nonredox-type (competitive) 5-LO inhibitors
such as CJ-13,610 or ZM230487, the potency is also high in intact
cells but low in cell-free assays [37,38]. However, reducing condi-
tions (e.g., presence of glutathione peroxidase and thiols such as
DTT) or low AA concentrations confer these inhibitors high effi-
ciency for repression of 5-LO [37,38]. In contrast to nonredox-
type 5-LO inhibitors [38], addition of 1 mM DTT to homogenates
of PMNL the potency of BRP-187 was not significantly altered
(Fig. 3C). Moreover, and again unlike nonredox-type (competitive)
5-LO inhibitors [38], lowering the AA concentration did not
improve the potency of BRP-187 (not shown), excluding this com-
pound as being a nonredox-type 5-LO inhibitor.
3.4. Direct targets of BRP-187 within the AA cascade
Since BRP-187 lost potency in A23187-activated PMNL and
monocytes in the presence of exogenous AA, we analyzed if thecompound blocked release of AA from endogenous sources, which
(besides acting on FLAP) might be another reason for the high cel-
lular potency. However, in [3H]AA-prelabeled monocytes, BRP-187
even at 10 lM did not suppress the A23187-induced release of [3H]
AA, while the cPLA2 inhibitor RSC-3388 (1 lM) markedly blocked
it, as expected (Fig. 4A). Moreover, unspecific interference of BRP-
187 with the viability of PMNL or monocytes can be excluded, as
30 min pre-incubation of the cells with 10 lM BRP-187 did not
affect cellular integrity (analyzed by trypan blue exclusion, not
shown) or metabolic activity over 24 h as monitored by MTT assay
in monocytes (Fig. 4B, staurosporine as control).
Our previous study revealed no significant effects of BRP-187
(up to 10 lM) on 5-LO-related dioxygenases that transform AA
such as 12/15-LOs, COX-1 and COX-2 [21]. However, the possibility
that FLAP is the major target prompted us to investigate if FLAP-
related enzymes out of the MAPEG family may be affected by
BRP-187 as well, which is the case for the structurally unrelated
FLAP inhibitor MK886 [39,40]. In fact, the activity of mPGES-1 that
converts PGH2 to PGE2 was concentration-dependently inhibited
by BRP-187 in a cell-free assay with an IC50 = 0.2 lM (Fig. 4D)
which even clearly outperforms MK886 (i.e., IC50 = 2.4 lM [41])
that served as control. Similarly, the MAPEG member LTC4 syn-
thase was blocked by BRP-187 with IC50 = 6 lM, again MK886
was used as reference (IC50 approx. 3 lM [40]) (Fig. 4C). Together,
BRP-187 prevents cellular 5-LO/FLAP complex assembly, thereby
potently suppressing 5-LO product biosynthesis in the one-digit
nanomolar range, but also directly inhibits the activity of the
MAPEG members mPGES-1 and LTC4 synthase as well as 5-LO at
higher concentrations without affecting the 5-LO-related dioxyge-
nases 12/15-LOs and COX-1/2.
3.5. Anti-inflammatory effectiveness of BRP-187 and inhibition of LT
biosynthesis in vivo
In view of the high potency of BRP-187 for suppression of cellu-
lar LTB4 and cysLT formation we attempted to evaluate the anti-
inflammatory effectiveness and inhibition of LT biosynthesis
A B C
0.3 3 30
0
25
50
75
100
w/o
0.01 % Triton
0.1% Triton
BRP-187 [µM]
5-
LO
 p
ro
du
ct
 fo
rm
at
io
n
(%
 o
f c
on
tr
ol
)
0.1 1 10
0
25
50
75
100
      BRP-187 [µM]
-  DTT
+ DTT
5-
LO
 p
ro
du
ct
 fo
rm
at
io
n
(%
 o
f c
on
tr
ol
)
1 10 10 (1)
0
25
50
75
100
**
BRP-187 [µM]
5-
LO
 p
ro
du
ct
 fo
rm
at
io
n
(%
 o
f c
on
tr
ol
)
Fig. 3. BRP-187 inhibits 5-LO product formation in cell-free assays. (A) Reversible inhibition of 5-LO by BRP-187. Purified 5-LO (0.5 lg/ml) was incubated with 1 lM or 10 lM
BRP-187 for 15 min at 4 C. An aliquot of the 10 lM sample was 10-fold (‘‘10 (1)”) diluted with assay buffer, while the other aliquot was not altered. The samples were then
prewarmed for 30 s at 37 C and 2 mM CaCl2 and 20 lM AA were added. After 10 min, 5-LO product formation was analyzed by HPLC. ⁄⁄, p < 0.01 versus inhibition without
dilution, ANOVA + Bonferroni post hoc test; n = 3. (B) Purified 5-LO (0.5 lg/ml) was incubated with BRP-187 in the absence or presence of 0.01% or 0.1% triton-X 100 at 4 C for
15 min, and 5-LO activity was determined as described above. Data are expressed as percentage of control (100%) and given as mean ± SEM, n = 4. (C) Effects of DTT on 5-LO
inhibition by BRP-187. PMNL homogenates (corresponding to 5  106 cells/ml) were pre-incubated with BRP-187 or vehicle (DMSO, 0.1%) with or without 1 mM DTT at 4 C
for 15 min. Samples were then pre-warmed for 30 s at 37 C, 2 mM CaCl2 and 20 lM AA were added, and after 10 min 5-LO product formation was determined. Data are
expressed as percentage of control (100%), mean ± SEM, n = 3.
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Fig. 4. Effects of BRP-187 on cellular AA release, cell viability, LTC4 synthase activity and mPGES-1 activity. (A) Cellular AA release. Analysis of radioactivity in supernatants of
[3H]AA-labeled monocytes treated with vehicle (0.1% DMSO) and after pre-incubation with 10 lM BRP-187 or 1 lM cPLA2 inhibitor (RSC-3388) and stimulation with 2.5 lM
A23187. Data are expressed as percentage of control (100%), mean ± SEM, n = 4. ⁄, p < 0.05, versus vehicle control. (B) Cell viability. Monocytes were treated with BRP-187,
staurosporine (stsp, 3 lM) or vehicle (0.3% DMSO) for 24 h and cell viability was analyzed by MTT assay. Data are expressed as percentage of control (100%), mean ± SEM,
n = 3. ⁄⁄, p < 0.005 versus vehicle control. (C) LTC4 synthase activity. LTC4 synthase-containing microsomes from transfected HEK293 cells were pre-incubated with BRP-187
or vehicle (0.1% DMSO) at 4 C for 10 min. Then, samples were pre-warmed for 1 min at 37 C and 1 lM LTA4-methyl ester was added. After 10 min the reaction was stopped
and LTC4 methyl ester was analyzed. Data are expressed as percentage of control (100%), mean ± SEM, n = 3. (D) mPGES-1 activity. Microsomes of IL-1b-stimulated A549 cells
were pretreated with BRP-187 treated at 4 C for 10 min and 20 lM PGH2 was added. After 1 min at 4 C, the reaction was stopped and PGE2 was analyzed. Data are expressed
as percentage of control (100%), mean ± SEM, n = 4.
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(n = 6 per group) received i.p. BRP-187 (1, 3, or 10 mg/kg), MK886
(1 or 3 mg/kg), zileuton (10 mg/kg) or vehicle (2% DMSO in saline)
30 min prior to i.p. zymosan injection. Thirty min after zymosan,
vascular permeability was analyzed and exudates were collected
for measuring cysLT levels, and after 4 h, exudates were collected
for analysis of leukocyte infiltration and MPO activity. BRP-187Table 2
Effects of BRP-187 in vivo on cysLT levels in zymosan-induced peritonitis. Male mice
(n = 6, each group) were treated i.p. with BRP-187, MK886, zileuton or vehicle, 30 min
before i.p. injection of zymosan. Analysis of cysLT levels by ELISA was performed
30 min after zymosan injection. *p < 0.05; ***p < 0.001 versus vehicle (Anova
+ Bonferroni).
Treatment CysLTs
ng/ml % inhibition
Vehicle 87.3 ± 9.7 –
1 mg/kg BRP-187 81.7 ± 11.1 6%
3 mg/kg BRP-187 69.5 ± 9.9 20%
10 mg/kg BRP-187 34.6 ± 3.9⁄⁄⁄ 60%
1 mg/kg MK886 24.2 ± 2.9⁄⁄⁄ 72%
10 mg/kg zileuton 56.5 ± 4.6⁄ 35%dose-dependently reduced cysLT levels by 20% at 3 mg/kg and
60% at 10 mg/kg. MK886 (1 mg/kg) decreased cysLT levels by 72%
and zileuton (10 mg/kg) by 35% (Table 2). BRP-187, at 10 mg/kg,
also significantly attenuated (33%) the increased vascular perme-
ability (Table 3), the infiltration of leukocytes (57%), and com-
pletely abolished MPO activity (Table 4). The FLAP reference
inhibitor MK886 also prevented vascular permeability (51% atTable 3
Effects of BRP-187 on vascular permeability in zymosan-induced peritonitis. Male
mice (n = 6, each group) were treated i.p. with BRP-187, MK886, zileuton or vehicle,
30 min before i.p. injection of zymosan. Analysis of vascular permeability was
performed 30 min after zymosan injection. *p < 0.05; ***p < 0.001 versus vehicle (t-
test); n.i., no inhibition.
Treatment Vascular permeability
A610 % inhibition
Vehicle 0.623 ± 0.035 –
10 mg/kg BRP-187 0.417 ± 0.071⁄ 33%
3 mg/kg MK886 0.303 ± 0.018⁄⁄⁄ 51%
10 mg/kg zileuton 0.639 ± 0.104 n.i.
Table 4
Effects of BRP-187 on cell infiltration in zymosan-induced peritonitis. Male mice (n = 6, each group) were treated i.p. with BRP-187, MK886, zileuton or vehicle, 30 min before i.p.
injection of zymosan. Analysis of leukocyte infiltration and MPO was performed 4 h after zymosan injection. ***p < 0.001 versus vehicle (t-test).
Treatment Infiltration of leukocytes MPO activity
106 % inhibition U/ml % inhibition
Vehicle 7.6 ± 0.5 – 1.23 ± 0.13 –
10 mg/kg BRP-187 3.3 ± 0.6⁄⁄⁄ 57% 0⁄⁄⁄ 100%
1 mg/kg MK886 4.5 ± 0.3⁄⁄⁄ 41% 0.72 ± 0.13⁄⁄⁄ 41%
24 U. Garscha et al. / Biochemical Pharmacology 119 (2016) 17–263 mg/kg) and it impaired leukocyte infiltration (41%) and MPO
activity (42%) at 1 mg/kg (Tables 3 and 4).
4. Discussion
We here present the 4,5-diarylisoxazol-3-carboxylic acid
derivative BRP-187 as highly potent inhibitor of cellular 5-LO pro-
duct biosynthesis in human PMNL and monocytes with IC50 of 7–
10 nM upon cell activation by LPS and fMLP that are pathophysio-
logical relevant stimuli [34]. In mouse zymosan-induced peritoni-
tis, BRP-187 exhibits marked effectiveness as LT biosynthesis
inhibitor in vivo, and effectively suppressed vascular permeability
and infiltration of leukocytes which are the major biological func-
tions of cysLTs and LTB4, respectively [2]. Our mechanistic studies
using PLA suggest that BRP-187 acts primarily by preventing the
5-LO/FLAP complex assembly, a determinant for cellular LT biosyn-
thesis [2,8], but affects 5-LO enzymatic activity only at micromolar
concentrations, and fails to interfere with cellular AA release or cel-
lular viability.
Our results suggest that BRP-187 apparently interacts with
both, 5-LO and FLAP. Assignment of a given compound as FLAP
inhibitor is hampered by the circumstance that (i) FLAP is opera-
tive only in intact cells and (ii) FLAP possesses no enzymatic activ-
ity or any function that can be easily monitored as read-out
reflecting functional FLAP interference. Nevertheless, we provide
several lines of evidence that BRP-187 interferes with the function
of FLAP. First, our previous docking studies and MD simulations
using the 3D structure of FLAP (PDB code 2Q7M) reveal concrete
molecular interactions of BRP-187 with amino acids in the AA-
binding pocket and thus, strongly support FLAP binding [21]. Sec-
ond, the potent suppression of cellular 5-LO product biosynthesis
in PMNL and monocytes was clearly impaired by provision of
excess of exogenous AA, which is a typical feature for FLAP inhibi-
tors [15,29,42]. Thus, FLAP facilitates access of endogenous AA to
5-LO [13,16,19] and supplementation of exogenous AA can circum-
vent the requirement for FLAP. Third, and strikingly, BRP-187 pre-
vented the agonist-induced 5-LO/FLAP complex assembly in
monocytes and PMNL analyzed by a previously established PLA
[11], a method that allows studying in-situ analysis of intracellular
protein-protein interactions [27]. This effect of BRP-187 was not
due to general blockade of 5-LO translocation to the perinuclear
region, even when higher concentrations of BRP187 (or MK886
as control) were used as compared to the PLA experiments. This
is in contrast, to hyperforin that prevents membrane-binding of
5-LO via interaction with the C2-like domain [43]. Of note,
MK886, a drug that was originally used as probe to identify FLAP
[36], revealed the same pattern: preventing 5-LO/FLAP complex
formation without blocking 5-LO translocation. In this respect,
the direct 5-LO inhibitor zileuton (used as control) was not effec-
tive in either experiment, as expected and shown before [11].
Direct inhibition of 5-LO activity by BRP-187 is clearly evident
in cell-free assays using PMNL homogenates and isolated human
recombinant 5-LO as enzyme source. In such assays, pure FLAP
inhibitors like MK886 are inactive [9,10,29,44]. Wash-out experi-
ments and studies using the nonionic detergent Triton X-100exclude irreversible 5-LO inhibition and unspecific (lipophilic)
aggregate-induced 5-LO interference, respectively. Note that in
contrast to direct redox-type and iron-chelating 5-LO inhibitors,
the so-called ‘‘competitive nonredox-type” 5-LO inhibitors (such
as CJ-13,610 [37] or ZM230487 [38]) show a similar pattern of dif-
ferential efficiency in cell-free and cell-based 5-LO assays, that is,
loss of potency in cell-free test systems. Therefore, BRP-187 could
act as nonredox-type 5-LO inhibitor with high potency only in
intact cells. However, lowering hydroperoxide levels by reconstitu-
tion of a reducing milieu (supplementation of GSH or DTT to PMNL
homogenates) restores efficient 5-LO inhibition by nonredox-type
inhibitors [45], which was not the case for BRP-187. Together,
BRP-187 specifically and reversibly interferes with 5-LO, albeit
only at 30- to 300-fold higher concentrations as compared to sup-
pression of 5-LO product biosynthesis in intact PMNL or
monocytes.
Because FLAP is member of the MAPEG family [46], we asked
whether BRP-187 may affect also other enzymes out of this class,
which in fact is the case for MK886 that blocks LTC4 synthase
[40] and mPGES-1 activity [39]. Although BRP-187 failed to inhibit
AA release in intact cells (this study) or other AA-converting dioxy-
genases like COX-1/2 or 12/15-LOs [21], it markedly suppressed
mPGES-1 activity and to a lower extent also LTC4 synthase activity.
In this respect, the high potency of BRP-187 against human
mPGES-1 is remarkable (IC50 = 0.2 lM versus 2.4 lM for MK886
[41] in a similar assay) and might be of pharmacological relevance
for the treatment of pain and inflammatory conditions. Further cel-
lular and preclinical studies warrant evaluation of (human and
rodent) mPGES-1 inhibition in more detail.
Despite the obvious value and benefit of anti-LT therapy for
many LT-related diseases such as asthma and allergic rhinitis,
CVD and cancer, there is still an unmet need for safe and efficient
drugs suitable for intervention in pharmacotherapy [47]. In fact,
there are currently several clinical trials ongoing with FLAP inhibi-
tors and promising results encourage for preclinical evaluations of
novel compounds [10]. Moreover, data from cohort studies suggest
a link between CVD and FLAP [48–51] and increased the interest in
developing agents that interfere with FLAP. It also seems that FLAP
inhibitors might outperform direct 5-LO inhibitors in in vivo exper-
iments, in preclinical studies, and in clinical trials [10]. In our LT-
related model of murine peritonitis induced by zymosan [30],
BRP-187 (as well as MK886) was highly efficient in reducing the
cysLT levels in vivo after i.p. application and in this respect outper-
formed the direct 5-LO inhibitor zileuton. Accordingly, one of the
major bioactivities of cysLTs, i.e. increase of vascular permeability
[52], was significantly blocked under these conditions by BRP-187
but not so by zileuton at the same dose. Along these lines, infiltra-
tion of leukocytes into the peritoneal cavity, which is potently eli-
cited by the powerful chemotactic LTB4 [53], was inhibited by BRP-
187 in the zymosan-induced peritonitis model. Therefore, our data
support the concept of FLAP interference as pharmacological ther-
apy of LT-related diseases and highlight BRP-187 as novel type of
efficient inhibitor of the FLAP/5-LO complex assembly.
MK886, an indole derivate that inhibits LT formation in vitro
and in vivo was used as tool/probe to identify FLAP [36], and thus
U. Garscha et al. / Biochemical Pharmacology 119 (2016) 17–26 25represented the first FLAP inhibitor [18,54] that was assessed up to
phase II clinical studies. Subsequently, the quinoline-class com-
pound BAY X1005 (syn. DG-031) from Bayer [55], and the
quinoline-indole hybrid MK591 [56] were presented as FLAP inhi-
bitors that effectively inhibited LT biosynthesis. Although these
compounds could enter phase II clinical trials, the clinical evalua-
tions were discontinued for unknown reasons. However, novel
derivatives of MK886 such as AM103 and the follow-up compound
AM803 (now GSK2190915) were recently developed that potently
inhibited LTB4 formation with acceptable pharmacokinetics and
preclinical toxicology [44,57,58]. GSK2190915 underwent several
phase II clinical trials for treatment of asthma with partially
promising results.
Taken together, BRP-187 represents a novel chemotype of LT
biosynthesis inhibitors with outstanding potency in human PMNL
and monocytes activated under pathophysiological relevant condi-
tions and with effectiveness in vivo. Using the PLA that visualizes
the in situ interaction between 5-LO and FLAP in intact cells during
LT formation, we demonstrate that BRP-187 prevents 5-LO/FLAP
complex assembly without blocking 5-LO nuclear redistribution.
In light of the unmet need for effective and safe anti-LT drugs
and the novel therapeutic indication for FLAP inhibitors, BRP-187
deserves attention and further preclinical assessment of the com-
pound is warranted.
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